Wedbush reiterated its BioMarin Pharmaceuticals BMRN Neutral rating and reduced its fair value from $36 to $35 in a research report published today.
In the report, Wedbush stated, "Among the numerous catalysts in the remainder of 2012, we believe release of Phase 3 results from the GALNS trial in Q4 is likely to have the strongest impact on BMRN valuation."
Shares of BioMarin closed today at $36.34, down 0.03% from Thursday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in